What does ADMA bio manufacturing — stock-based comp mean?

Reflects the non-cash expense recognized for equity-based awards granted to employees and executives within the manufacturing business unit. This metric is used to understand the cost of talent retention and alignment of incentives with shareholder interests.

ADMA Biologics (ADMA) ADMA Bio Manufacturing — Stock-Based Comp

Screener

Other segment segments

Plasma Collection Centers

$1.03M-10.9%

Similar metrics at other companies

NXT

NXTTCODM — Stock-Based Comp

$3.55M—

LFVNReportable — Stock-Based Comp

$704K-53.7%

ODYSCorporate — Stock-Based Comp

$886K+9.9%

MCSTheatres — Stock-Based Comp

$247K+32.1%

SPCXAI — Stock-Based Comp

$516M+109%

SPCXConnectivity — Stock-Based Comp

$136M+49.5%

Other financials

Income statement

See full

Revenue$124.4M+2.0%

Gross profit$86.3M+28.3%

Operating income$52.4M+22.5%

Net income$37.8M+10.5%

EPS (diluted)$0.16+14.3%

Balance sheet

See full

Cash & equivalents$136.0M+50.7%

Total debt$203.9M+1,855%

Total equity$408.2M+2.5%

Total assets$684.2M+22.5%

Cash flow

See full

Operating cash flow$29.5M+39.7%

CapEx$2.3M-6.9%

Free cash flow$27.3M+45.8%

Valuation

See full

Market cap$2.25B-49.1%

Enterprise value$2.32B-46.6%

P/E13.3×-7.9×

P/S4.4×-4.9×

Profitability

See full

Gross margin64.7%+11.7pp

Operating margin43.8%+11.0pp

Net margin33%-11.1pp

FCF margin22.7%+8.9pp

Returns & leverage

See full

Return on equity41.9%-29.3pp

Debt / equity0.5×+0.5×

Current ratio7×+1.6×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 5:16 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001140361-26-031445

(in thousands)	ADMA Bio Manufacturing	Plasma Collection Centers	Total
Revenues	$$123,637	$723	124,360
Cost of product revenue	37,564	554	38,118
Research and development	6,014	-	6,014
Plasma center operating expenses	-	1,026	1,026
Gain on sale of plasma centers	-	-	-
Selling, marketing and distribution	7,634	-	7,634
Depreciation and amortization expense	1,281	499	1,780
General and administrative expense	8,340	-	8,340

Item 1. Financial Statements.

FAQ

What is ADMA Biologics's ADMA bio manufacturing — stock-based comp?: ADMA Biologics (ADMA) reported ADMA bio manufacturing — stock-based comp of $0 in Q2 2026.
What does ADMA bio manufacturing — stock-based comp mean?: Reflects the non-cash expense recognized for equity-based awards granted to employees and executives within the manufacturing business unit. This metric is used to understand the cost of talent retention and alignment of incentives with shareholder interests.